新桥生物计划于2026年第四季度启动以客观缓解率为主要终点的注册性三期联合试验

美股速递
Yesterday

新桥生物(NovaBridge Biosciences)宣布,公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率(ORR)作为主要疗效终点,旨在评估创新疗法组合在目标患者群体中的治疗效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10